Lantheus announces FDA approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection. Learn more.

Because we’re making headlines

Please visit our investor site for a complete list of recent and archived press releases, follow us on LinkedIn for social media updates and browse below for additional media resources.

Latest press releases

See all press releases

Press release

March 6, 2026

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Read more

Press release

March 2, 2026

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

Read more

Press release

February 26, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Read more

Additional resources

Media library

Images, videos and other assets bring news about Lantheus to life.

Events

Events allow us to connect with our people, patients and partners.

Investors

All investor resources can be found on our dedicated investor website.

Contact

Media

Melissa Downs
Executive Director
External Communications

646-975-2533

media@lantheus.com

Investors

Mark Kinarney
Vice President
Investor Relations

978-671-8842

ir@lantheus.com